Miraculins Announces Grant of Options

Miraculins Inc. (TSX VENTURE:MOM), a medical diagnostic company focused on
acquiring, developing and commercializing diagnostic tests and risk assessment
technologies for unmet clinical needs, announces that it has granted an
aggregate of 1,068,500 stock options at an exercise price of $0.22 per common
share, to certain directors, officers, employees, consultants and management
company employees of the Company. The options are set to expire five years from
the date of grant and are subject to the approval of the TSX Venture Exchange
and the terms of Miraculins' stock option plan. 


Neither the TSX Venture Exchange nor its Regulation Services Provider (as that
term is defined in the policies of the TSX Venture Exchange) accepts
responsibility for the adequacy or accuracy of this release. 


FOR FURTHER INFORMATION PLEASE CONTACT: 
Miraculins Inc.
Christopher J. Moreau
President & CEO
204-477-7599
204-453-1596 (FAX)
info@miraculins.com
www.miraculins.com

Miraculins Inc. (TSXV:MOM)
過去株価チャート
から 5 2024 まで 6 2024